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BACKGROUND 
 
             Tuberculosis (TB) is the most common cause of infectious disease–related mortality 
worldwide. Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due 
to a single infectious agent.
[1]
 
 
           The World Health Organization estimates that 2 billion people have latent TB, while 
another 3 million people worldwide die of TB each year. In 2012, 8.6 million people fell ill with 
TB and 1.3 million died from TB.
[2] 
             In addition, the prevalence of drug-resistant TB is also increasing worldwide. Co-
infection with HIV has been an important factor in the emergence and spread of 
resistance.
[22] 
New TB treatments are being developed and new TB vaccines are currently under 
investigation.
[3]
 TB is a major global health threat, and we must improve the existing treatment 
regimen to control the spread of TB. 
INTRODUCTION  
             Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often 
affect the lungs. Tuberculosis is curable and preventable. It has been recorded in history since the 
Greco-Roman and Egyptian civilizations.
[4]
 In 1882, German Physician Robert Koch isolated the 
bacterium. 
 
                Tuberculosis is contagious and airborne. It is spread from person to person through the 
air. When people infected with lung TB cough, sneeze or spit, they force the TB germs into the 
air. A healthy person needs to inhale only a few of these germs to become infected.
[4]
  
 
MYCOBACTERIUM TUBERCULOSIS 
 
                 Mycobacterium tuberculosis is caused by the rod-shaped, non–spore-forming, aerobic 
bacterium.
[22]
 Being an aerobic bacterium meaning it needs oxygen to survive. During active TB 
disease, Mtb complexes are always found in the upper air sacs of the lungs due to this reason. 
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Mycobacterium typically measure 0.5 μm by 3 μm, are classified as acid-fast bacilli and have a 
unique cell wall structure crucial to their survival.
[4] 
 
 
Fig 1: Electron microscope image of Mycobacterium tuberculosis 
 
Cell wall  
The well developed cell wall contains a considerable amount of a fatty acid, mycolic acid, 
covalently attached to the underlying peptidoglycan-bound polysaccharide arabinogalactan, 
providing a peculiar lipid barrier. This barrier is responsible for many of the medically 
challenging physiological characteristics of tuberculosis, including resistance to antibiotics and 
host defense mechanisms. The composition and quantity of the cell wall components affect the 
bacteria‟s virulence and growth rate. The peptidoglycan polymer confers cell wall rigidity.[4] 
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Fig 2: Mycobacterial cell wall (1-outer lipids, 2-mycolic acid, 3-polysaccharides, 4-
peptidoglycan, 5-plasma membrane, 6- lipoarabinomannan, 7-phosphatidyllinositol mannoside, 
8- cell wall skeleton) 
 
PATHOPHYSIOLOGY 
 
             After inhalation, the infectious droplets settle throughout the airway. The majority of the 
bacilli are trapped in the upper parts of the airways as there are mucus-secreting goblet cells 
here.  
 
              Bacteria in droplets that bypass the mucociliary system which reach the alveoli are  
surrounded and engulfed by alveolar macrophages. These macrophages are a part of the innate 
immune system and provide an opportunity for the body to destroy the invading mycobacteria 
and prevent infection. Macrophages are the readily available phagocytic cells that combat many 
pathogens without requiring a previous exposure to the pathogen. 
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               The mycobacterial lipoarabinomannan is a vital ligand for a macrophage receptor. The 
complement system also plays a major role in the phagocytosis of the bacteria. The complement 
protein C3 binds to the cell wall and enhances recognition of the mycobacteria by macrophages. 
Opsonization by C3 is rapid. The subsequent phagocytosis by macrophages initiates a cascade of 
events that results in either successful control of the infection, followed by latent tuberculosis, or 
progression to active disease, called primary progressive tuberculosis.  
  
                After being ingested by macrophages, the mycobacteria continue to multiply slowly, 
with bacterial cell division occurring every 25 to 32 hours. Regardless of whether the infection 
becomes controlled or progresses, initial development involves production of proteolytic 
enzymes and cytokines by macrophages in an attempt to degrade the bacteria.
[4] 
 
                Released cytokines attract T lymphocytes, the cells that constitute cell-mediated 
immunity. Macrophages then transfers mycobacterial antigens on their surface to the T cells. 
This initial immune process continues for 2 to 12 weeks; the microorganisms continue to grow 
until they reach sufficient numbers to fully elicit the cell-mediated immune response. 
 
                For persons with intact cell mediated immunity, the next step is formation of 
granulomas around the organism. These lesions are formed from an accumulation of activated T 
lymphocytes and macrophages.This environment destroys macro phages and produces early 
solid necrosis at the center of the lesion. By 2 or 3 weeks, the necrotic environment resembles 
soft cheese, and termed caseous necrosis, and is characterized by low oxygen levels, low pH, and 
limited nutrients. This condition restricts further growth of the organism and establishes latency. 
 
             In patients infected with Mtb, droplets can be coughed up from the bronchus and infect 
other people. If discharge into a vessel occurs, extra pulmonary tuberculosis is likely to occur. 
Bacilli may also drain into the lymphatic system and collect in the tracheobronchial lymph nodes 
of the affected lung, where the organisms can form new caseous granulomas.
[4] 
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Fig 3: Pathophysiology of tuberculosis: inhalation of bacilli (A), containment in agranuloma (B), 
and breakdown of the granuloma in less immunocompetent individuals (C). 
 
THE NEED FOR NOVEL TUBERCULOSIS DRUGS 
 
 to improve current treatment by shortening the total duration of treatment . 
 to improve the treatment of MDR TB[5] 
 to provide for more effective treatment of latent tuberculosis infection.[4] 
 New drugs to improve current drugs that facilitate compliance by providing for less 
intensive supervision are also of great interest. 
 Discovery of a compound that would reduce both the total length of treatment and the 
frequency of drug administration.
[6]
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 MDR TB must be treated with a combination of “second line” drugs, which are not only 
more expensive but also much more toxic and less effective than the drugs used in 
standard therapy. 
MEDICINAL CHEMISTRY  
 
              Medicinal Chemistry concerns with the discovery, development, identification and 
interpretation of the mode of action of biologically active compounds at the molecular level. 
Medicinal Chemistry is also concerned with the study, identification and synthesis of the 
metabolic products of these drugs and related compounds. It is a multi disciplinary approach 
drawing out theoretical chemistry, organic chemistry, analytical chemistry, molecular biology, 
pharmacology and bio-chemistry.
[7] 
 
DRUG DISCOVERY  
 
              The process of drug discovery is very complex and requires an interdisciplinary effort to 
design effective and commercially feasible drugs. Earlier drug discovery has been a trial-and-
error process.The process of drug development has evolved with time. New understanding of the 
quantitative relationship between structure and biological activity ushered the beginning of 
computer-aided drug design.
[8] 
With the help of computers, a new era has begun in drug 
discovery. The development cost will be cut by almost a third. The development times are 
reduced.  
 
LEAD AND LEAD OPTIMIZATION
 
  
 
                  A Lead is defined as a compound, usually a small organic molecule that demonstrates 
desired biological activity on a validated molecular target. Lead optimization is a technique of 
refining 3D structures of drug molecules and promoting the binding of drug to protein active 
sites. In this technique the modification of the structure of the drug molecules is done by docking 
every specific structure of a drug compound in active site of protein, and calculating the extent of 
their interactions.
[13]
 Optimization aids in the structural modification of newer molecules in order 
to improve the physico-chemical properties and biological activity for a given set of compounds 
in the library.
[8]
 Further structural modification improves the affinity, reactivity towards target 
and enhances stability during metabolism. 
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COMPUTER AIDED DRUG DESIGN 
 
 
            Computer-aided drug design uses computational chemistry to discover, enhance, or study 
drugs and related biologically active molecules. The fundamental goal is to predict whether a 
given molecule will bind to a target. Molecular mechanics or molecular dynamics are most often 
used to predict the conformation of the small molecule and to model conformational changes in 
the biological target. This provides semi-quantitative prediction of the binding affinity. .
[9]
  
 
           Ideally the computational method should be able to predict the affinity before a compound 
is synthesized. The reality however is that present computational methods are imperfect and 
provide at best only qualitatively accurate estimates of affinity. Therefore in practice it still takes 
several iterations of design, synthesis, and testing before an optimal molecule is discovered. On 
the other hand, computational methods have accelerated discovery by reducing the number of 
iterations required and in addition have often provided more novel small molecule structures. 
 
          Drug design with the help of computers may be used at any of the following stages of drug 
discovery: 
1. hit identification using virtual screening (structure- or ligand-based design) 
2. Hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, 
etc.) 
3. lead optimization, optimization of other pharmaceutical properties while maintaining      
affinity
[9]
  
          In order to overcome the insufficient prediction of binding affinity calculated by recent 
scoring functions, the protein-ligand interaction and compound 3D structure information are used 
to analysis. 
 
RATIONAL DRUG DESIGN  
 
            Rational drug design can be broadly divided into two categories: 
(A) Development of small molecules with desired properties for targets, biomolecules (proteins 
or nucleic acids), whose functional roles in cellular processes and 3D structural information are 
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known. This approach in drug design is well established and is being applied extensively by the 
pharmaceutical industries. 
(B) Development of small molecules with predefined properties for targets, whose cellular 
functions and their structural information may be known or unknown. Knowledge of unknown 
targets (genes and proteins) can be obtained by analyzing global gene expression data of samples 
untreated and treated with a drug using advanced computational tools. 
 
               Once a target is identified, then both approaches (A) and (B) for development of small 
molecules require examination of several aspects. These aspects include the evaluation of 
binding scores (affinity/specificity), balance between hydrophilicity/lipophilicity, absorption, 
distribution, metabolism and excretion (ADME), electrophilic, nucleophilic, and radical attack 
(biodegradation), toxicity of the parent small molecules, and products due to biotransformation 
in the different phases of metabolism, quantitative structure–activity relationship (QSAR), and 
quantitative structure–property relationship (QSPR) respectively.[10] 
 
TYPES OF DRUG DESIGN  
 
             Advances in computational techniques and hardware have facilitated the application of 
in silico methods in the discovery process. Drug Design can be categorized as two types:  
 Structure based drug design (SBDD)  
 Ligand based drug design (LBDD). 
Ligand Based Drug Design  
 
            It is also called indirect drug design. Ligand based drug design is an approach used in the 
absence of the receptor 3D information and it relies on knowledge of molecules that bind to the 
biological target of interest. 3D quantitative structure activity relationships (3D QSAR) and 
pharmacophore modeling are the most important and widely used tools in ligand based drug 
design. They can provide predictive models suitable for lead identification and optimization.
[11] 
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Fig 4: Ligand based drug design 
Structure Based Drug Design  
 
                 SBDD is the approach where the structural information of the drug target is exploited 
for the development of its inhibitor. Receptor structure(s) is a prerequisite for this method. Most 
commonly the structure of the receptor is determined by experimental techniques such as X-ray 
crystallography or NMR. If the structure of the protein drug target is not available, protein 
structure can be predicted by computational methods like threading and homology modeling.  
 
                Threading (also called as fold) is a modeling approach used to model proteins that do 
not have homologous proteins with known structure. In threading, a given amino acid sequence 
is searched for compatibility with the structures in a database of known folds. The structure of 
the query protein is built from these folds. 
 
               Homology modeling (also called as comparative) is an approach that relies on a clear 
relationship or homology between the sequence of the target protein and at least one known 
structure. The process of homology modeling of proteins consists of the following steps: 
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Identification of homologous protein with known 3D structure(s) that can serve as template; 
sequence alignment of target and template proteins; generation of model for the target based on 
the 3D structure of the template and the alignment; model refinement and validation. Over the 
years, homology modeling has become the main alternative to get a 3D representation of the 
target in the absence of crystal structures.
[11] 
 
Fig 5: Structure based drug design 
 
DOCKING
  
 
              Docking involves the fitting of a molecule into the target structure in a variety of 
positions, conformations and orientations.  Molecular docking is used to predict the structure of 
the intermolecular complex formed between two molecules.
[12]
 The small molecule called Ligand 
usually interacts with protein‟s binding sites. Binding sites are areas of protein known to be 
active in forming of compounds. There are several possible mutual conformations in which 
binding may occur. These are commonly called binding modes. It also predicts the strength of 
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the binding, the energy of the complex; the types of signal produced and calculate the binding 
affinity between two molecules using scoring functions. The most interesting case is the type 
protein-ligand interaction, which has its applications in medicine.
[13] 
 
TYPES OF DOCKING  
 
 Lock and Key\Rigid Docking [13] – In rigid docking, both the internal geometry of the 
receptor and ligand is kept fixed and docking is performed.  
 Induced fit\Flexible Docking [13] - An enumeration on the rotations of one of the 
molecules (usually smaller one) is performed. Every rotation the surface cell occupancy 
and energy is calculated; later the most optimum pose is selected.  
 
STEPS INVOLVED IN DOCKING 
 
 
1. Building the Receptor: The 3D structure of the receptor can be downloaded from PDB and 
then the structure should be processed.Processing should include removal of the water molecules 
from the cavity, stabilizing the charges, filling the missing residues, generation the side chains 
etc according to the parameters available. The receptor should be biological active and stable 
state. 
 
2. Identification of the Active Site: After the receptor is built, the active site within the receptor 
should be identified. The receptor may have many active sites but the one of the interest should 
be selected. Most of the water molecules and heteroatom if present should be removed.  
 
3. Ligand Preparation: Ligands can be obtained from various databases like ZINC, PubChem 
or can be sketched using tools such as Chemsketch. While selecting the ligand, the Lipinski‟s 
Rule of 5 should be applied. The rule is important for drug development where a 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity, as well as drug-like properties as described. 
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4. Docking: This is the last step, where the ligand is docked onto the receptor and the 
interactions are checked. The scoring function generates score depending on which the best fit 
ligand is selected. 
 
SCORING FUNCTION 
 
 
             These are mathematical methods used to predict the strength of the non-covalent 
interaction called as binding affinity, between two molecules after they have been docked. 
Scoring functions have also been developed to predict the strength of other types of 
intermolecular interactions, for example between two proteins or between protein and DNA or 
protein and drug. These configurations are evaluated using scoring functions to distinguish the 
experimental binding modes from all other modes explored through the searching algorithm.
[13] 
 
ADME ANALYSIS  
 
For a drug to be pharmacologically active and exert the action it should posses pharmacokinetic 
properties like absorption, distribution, metabolism and excretion. In the field of drug research 
and development many drug failures do occur, as they do not undergo these properties 
satisfactorily. This has to be ruled out earlier in the process of drug discovery. Many in-vitro 
studies are more frequently used to evaluate ADME properties. Some computational methods ( 
in silico tools) have been evolved to investigate the most suitable drug molecules. 
 
Prediction of ADME related properties 
 
Absorption: 
 
To investigate this in silico models uses simple parameters like log D (diffusion coefficient) and 
polar surface area are the descriptors foe hydrogen bonding capacity and log P (partition co 
efficient) values should fall under the prescribed values as per the  Rule of Five, which 
determines the absorption.
[14]
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Bioavailability: 
            Size and shape of the molecule, lipophilicity and flexibility determines the bioavailability 
of the molecule. 
 
Metabolism: 
 
            Various in silico approaches are existing in evaluating the metabolism namely QSAR and 
3D QSAR. Apart from those computational chemists have updated the structural details in the 
data bases and tools for predicting metabolism. 
[14] 
 
EVALUATION OF INSILICO TOXICITY  
 
              Toxicity is one of the major criteria to be considered for a molecule to shine as a 
successful clinical candidate in pharmaceutical research. About 20-40 % of drug failure comes 
under this category. Commercial in silico tools estimates toxicity and provides information by 
the use of QSAR (parameters and descriptors), scientific literatures and to some extent in 
abstracting issues from humans.
[15] 
 
               In silico approaches like OSIRIS property explorer predicts the carcinogenicity, 
mutagenicity, teratogenicity, immune toxicology, irritation, sensitization, etc. Newly updated 
tools help in evaluating hepato, neuro and cardio toxicity. 
 
CHARACTERIZATION 
 
 
IR SPECTROSCOPY 
Infrared (IR) spectroscopy is one of the most common spectroscopic techniques used by organic 
chemists. The main goal of IR spectroscopic analysis is to determine the chemical functional 
groups in the sample.
[16]
 Different functional groups absorb characteristic frequencies of IR 
radiation. IR spectroscopy is an important and popular tool for structural elucidation and 
compound identification. 
            The possible characteristic bands of the nucleus are 
1. 3300-3540 cm-1 N-H Stretching Vibration 
2. 3670-3230 cm-1 O-H Stretching Vibration 
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3. 1690-1630 cm-1 C=N Stretching Vibration 
4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration 
5. 3100-3000 cm-1 C-H Aromatic Stretching Vibration 
NMR SPECTROSCOPY 
             
          NMR is the most powerful analytical tool currently available to an organic chemist. NMR 
allows characterization of a very small amount of sample (10mg), and does not destroy the 
sample (non-destructive technique). NMR spectra can provide vast information about a 
molecule's structure and can very often be the only way to prove what the compound really is. 
Typically though, NMR is used in conjunction with other types of spectroscopy and chemical 
analysis to fully confirm a complicated molecule's structure. It involves the interaction of the 
electromagnetic radiation and the hydrogen of the nucleus when placed in an external static 
magnetic field.
[17] 
 
Some basic characteristic peaks of the nucleus 
1. Aromatic and hetero aromatic compounds 6-8.5 δ 
2. Alcoholic hydroxyl protons 1-5.5 δ 
3. Aldehyde protons 9-10 δ 
 
MASS SPECTROSCOPY 
             Mass Spectrometry is an analytic technique that utilizes the degree of deflection of 
charged particles by a magnetic field to find the relative masses of molecular ions and fragments. 
It is a powerful method because it provides a great deal of information and can be conducted on 
tiny samples. Mass spectrometry has a number of applications in organic chemistry. They are: 
 Determining molecular mass 
 Finding out the structure of an unknown substance 
 Verifying the identity and purity of a known substance 
 Providing data on isotopic abundance[16] 
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BIOLOGICAL EVALUATION 
 
Anti tubercular Activity 
[18] 
 
There are various high throughput assays available for screening of new chemical entities against 
tuberculosis. They are: 
 Microplate Alamar Blue Assay 
 BACTEC Assay 
 Luciferous reporter phage assay 
 REMA Assay 
 Broth Dilution Assay 
 Middle brook(7H 9,7H 10,7H 11) Agar Dilution Assay 
THE ALAMAR BLUE ASSAY 
 
          Alamar Blue monitors the reducing environment of the living cell. The active ingredient is 
resazurin (IUPAC name: 7-hydroxy-10-oxidophenoxazin-10-ium-3-one), also known as diazo-
resorcinol, azoresorcin, resazoin, resazurine, which is water-soluble, stable in culture medium, is 
non-toxic and permeable through cell membranes. Continuous monitoring of cells in culture is 
therefore permitted. 
         Growth is measured quantitatively by a visual colour change and the amount of 
fluorescence produced is proportional to the number of the living cells which is determined by 
colorimetric and fluorimetric methods. 
 
Chemistry 
N
OO
Na
O
N
OO
Na
O
 
                            O 
 
              Resazurin (oxidized)                                                         Resorufin (reduced) 
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Redox principle 
[19] 
 
       This assay is an indirect colorimetric DST method for determining the MIC of TB drug 
strains of Mycobacterium tuberculosis. The redox indicator Alamar blue monitors the reducing 
environment of the living cell. It turns from blue to pink in the presence of mycobacterial 
growth. As the indicator dye accepts electrons it changes from the blue, oxidized, non 
fluorescent state to the pink, reduced, fluorescent state. The oxidation-reduction potential of 
Alamar Blue is +380 mV at pH 7.0, 25 °C. Alamar Blue, therefore, can be reduced by NADPH   
( Eo = 320 mV), FADH (Eo = 220 mV), FMNH (Eo = 210 mV), NADH (Eo = 320 mV), as well 
as the cytochromes (Eo = 290 mV to +80 mV). In addition to mitochondrial reductases, other 
enzymes (such as the diaphorases (EC 1.8.1.4, dihydrolipoamine dehydrogenase), NAD (P) H: 
quinine oxidoreductase and flavin reductase located in the cytoplasm and the mitochondria may 
be able to reduce Alamar Blue.  
 
ADVANTAGES 
 
 It has accurate time course measurement. 
 It has high sensitivity and linearity. 
 It involves no cell lysis. 
 It is ideal for use with post measurement functional assay. 
 It is flexible as it can be used with different cell models. 
 It is scalable and can be used with fluorescence and/or absorbance based instrumentation 
platforms. 
 It is non toxic, non-radioactive and is safe for the user. 
 
APPLICATIONS: 
 Especially meant for studies on Mycobacterium tuberculosis. 
 Used extensively in cell viability and cytotoxicity studies. 
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HETEROCYCLIC CHEMISTRY 
 
          Heterocyclic structures always are a part in the field of research and development in 
organic chemistry. Millions of heterocyclic structures are found to exist having special properties 
and biological importance. Among various compounds, I have chosen benzimidazole, a fused 
heterocyclic structure. 
 
BENZIMIDAZOLE NUCLEUS  
 
            It is a fused heterocyclic moiety. It is an important pharmacophore and a privileged 
structure in medicinal chemistry. This compound is bicyclic in nature which consists of the 
fusion of benzene and imidazole.
[20]
 Nowadays this is a moiety of choice which possesses many 
pharmacological properties. 
 
N
N
H
1H-benzimidazole
 
 
          The benzimidazole moiety is a versatile lead molecule. Literature survey conveys that 
benzimidazole derivatives are found to have wide range of biological activities like 
 Antimicrobial & antibacterial action 
 HIV Inhibitory activity 
 Anti Ulcer Activity 
 Antiproliferative activity 
 Antitumor activity 
 Anti-inflammatory activity 
 Antioxidant activity 
 Antiprotozoal activity 
 Androgen Receptor antagonist 
 Anti convulsant Agents 
Literature Review 
 
Department of Pharmaceutical Chemistry, MMC  Page 18 
 
GLUTAMINE SYNTHASE – THE TARGET 
Glutamine synthetase catalyzes the ligation of glutamate and ammonia to form glutamine, with 
the hydrolysis of ATP. The enzyme is a central component of bacterial nitrogen metabolism and 
is a potential drug target.
[25] 
Glutamate + ATP + NH3 → Glutamine + ADP + phosphate 
Structure 
Glutamine Synthetase can be composed of 8, 10, or 12 identical subunits separated into two face-
to-face rings. Bacterial GS are dodecamers with 12 active sites between each monomer. Each 
active site creates a „bifunnel‟ which is the site of three distinct substrate binding sites: 
nucleotide, ammonium ion, and amino acid.ATP binds to the top of the bifunnel that opens to the 
external surface. Glutamate binds at the bottom of the active site. The middle of the bifunnel 
contains two sites in which divalent cations bind (Mn
+2
 or Mg
+2
). One cation binding site is 
involved in phosphoryl transfer of ATP to glutamate, while the second stabilizes active GS and 
helps with the binding of glutamate. Hydrogen bonding and hydrophobic interactions hold the 
two rings of GS together. Each subunit possesses a C-terminus and an N-terminus in its 
sequence. The C-terminus (helical thong) stabilizes the GS structure by inserting into the 
hydrophobic region of the subunit across in the other ring. The N-terminus is exposed to the 
solvent. 
[21]
 
 
Fig 6: 4 ACF 
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Mechanism 
GS catalyzes the ATP-dependent condensation of glutamate with ammonia to yield glutamine. 
The hydrolysis of ATP drives the first step of a two-part, concerted mechanism.ATP 
phosphorylates glutamate to form ADP and an acyl-phosphate intermediate, γ-glutamyl 
phosphate, which reacts with ammonia, forming glutamine and inorganic phosphate. ADP and Pi 
do not dissociate until ammonia binds and glutamine is released.
[21] 
ATP binds first to the top of the active site near a cation binding site, while glutamate binds near 
the second cation binding site at the bottom of the active site. The presence of ADP causes a 
conformational shift in GS that stabilizes γ-glutamyl phosphate atom. Ammonium binds strongly 
to GS only if the acyl-phosphate intermediate is present. Ammonium, rather than ammonia, 
binds to GS because the binding site is polar and exposed to solvent. In the second step, 
deprotonation of ammonium allows ammonia to attack the intermediate from its nearby site to 
form glutamine. Phosphate leaves through the top of the active site, while glutamine leaves 
through the bottom (between two rings).
 [21] 
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AIM  
        The aim of this project is to discover molecules with potential anti-tubercular activity. 
 
OBJECTIVE 
 
        The compounds are designed and docked against a specific crucial target, Glutamine Synthase 1, 
which is involved in the cell wall biosynthesis and nitrogen metabolism. The synthesized compounds are 
expected to act on the same.  
       
         The plan of work includes: 
 Design of glutamine Synthase 1 inhibitors by docking studies. 
 Insilico Drug Likeness Prediction 
 Insilico Toxicity Assessment 
 Laboratory synthesis of the compounds with top G.Score 
 Characterization of the synthesized compounds by  
 Infrared Spectroscopy 
 1H Nuclear Magnetic Resonance Spectroscopy 
 Mass Spectroscopy 
 In-vitro anti tubercular activity of synthesized compounds (MABA)
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The whole study was carried out according to this flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-Silico investigation of Drug likeness and toxicological assessment  
Identification of basic nucleus 
Structural modification of the basic Nucleus 
Docking the molecule in the target protein 
Optimization of the highly Interacting molecules 
Top G score compounds selected 
Synthesis 
Characterization-Spectroscopy (IR, NMR, MASS) 
In-vitro anti tubercular activity by MABA 
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LITERATURE REVIEW 
 
1) Reviews related to the target- Glutamine Synthase 
 
Berlicki L.; Kafarski 
[22]
 studied about the Glutamine synthetase enzyme which catalyses the 
formation of glutamine from glutamate and ammonium ion. It is one of the most important 
enzymes in nitrogen metabolism. The first part of the review presents the long-dating research on 
inhibitors of glutamine synthetase. Analysis of their structure-activity relationships is presented 
in some detail. The second part of the paper is dedicated to potential medical applications of 
glutamine synthetase inhibitors, which is proved as effective anti-tuberculosis agent with high 
selectivity towards the pathogen.  
 
 
Marcus A.Horwitz et al 
[23]
 assessed the role of glutamine synthetase (GS), in the pathogenicity 
of Mycobacterium tuberculosis, glnA1 was constructed via allelic exchange. The mutant had no 
detectable GS protein or GS activity and was auxotrophic for L-glutamine. In addition, the 
mutant was attenuated for intracellular growth in human THP-1 macrophages. Based on growth 
rates of the mutant in the presence of various concentrations of L-glutamine the importance of 
the enzyme was known. These studies demonstrate that glnA1 is essential for M. tuberculosis 
virulence. 
 
 
Olof Lagerlund 
[24]
 synthesized some potential anti tubercular agents which targeted Glutamine 
Synthase.  Glutamine Synthetase (GS), is one of the latest targets of M.tb which catalyses the 
formation of glutamine from glutamic acid. In this work, novel GS inhibitors and new Pd (0) - 
catalyzed methods have been developed. 
 
 
Wojciech W. Krajewski et al 
[25]
 summarized that Glutamine synthetase catalyzes the ligation 
of glutamate and ammonia to form glutamine, with the hydrolysis of ATP. The enzyme is a 
central component of bacterial nitrogen metabolism  
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and is a potential drug target. This study provides the first reported structure for a taut form of 
the M. tuberculosis enzyme. The phospho compound, generated in situ by an active enzyme, 
mimics the phosphorylated tetrahedral adduct at the transition state. Some differences in ligand 
interactions of the protein with both phosphorylated compound and nucleotide are observed 
compared with earlier structures; a third metal ion also is found.  
 
 
Marcus A.Horwitz et al 
[26]   
investigated on a novel antibiotic strategy targeting the Glutamine 
Synthase enzyme of Mycobacterium tuberculosis using the highly demanding guinea pig model 
of pulmonary tuberculosis. The feasibility of inhibiting M. tuberculosis glutamine synthetase 
(GS), an enzyme that plays a key role in both nitrogen metabolism and cell wall biosynthesis was 
studied. 
 
 
2) Reviews related to Benzimidazole derivatives and its potential biological activities 
 
 
S. Sharma et al 
[27]
 studied various heterocyclic moieties and their antitubercular activity. 
Tuberculosis, a contagious infection caused by Mycobacterium tuberculosis, still remains the 
leading cause of the worldwide death among the infectious disease. Different heterocyclic 
moieties have been studied, synthesized and evaluated worldwide against M. tuberculosis to 
show their antitubercular activity. 
 
Ramanpreet Walia et al 
[20]
 reviewed on the benzimidazole derivatives .Benzimidazole 
derivatives play important role in medical field with so many pharmacological activities such as 
antimicrobial, antiviral, antidiabetic and anticancer activity. The potency of these clinically 
useful drugs in treatment of microbial infections and other activities encouraged the development 
of some more potent and significant compounds. This review is summarized to know about the 
chemistry of different derivatives of substituted benzimidazoles along with their pharmacological 
activities. 
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Kalyankar TM et al 
[28]
 have reviewed the various studies conducted on the benzimidazole 
derivatives. Benzimidazole derivatives play very efficient role in the medical field with plenty of 
therapeutic activities. Benzimidazole is an effective compound and there are a number of reviews 
available for biochemical and pharmacological studies which confirmed that these molecules are 
useful against a wide variety of microorganisms. Benzimidazole and its derivatives have been 
showing hopeful activity in the treatment of several diseases and for these reasons they achieved 
much attention as important pharmacophore and privileged structure in medicinal chemistry.  
 
 
Maste M. M. et al 
[29]
 aimed to synthes 
ize some benzimidazole acetic acid derivatives and also the derivatives associated with 1, 2,4 
triazolone and was investigated for their biological activities. All the compounds were screened 
for their anti tubercular and antimicrobial activities by standard methods. Results reveal that 
compounds show promising anti tubercular activity at both the concentration compared to 
standard drug streptomycin. 
N
N
Ar
O
N
N
N
H
N
+
O
-
O
O
 
 
 
M.Vijey Aanandhi et al 
[30]
 synthesized novel molecules with benzimidazole nucleus and 
further formed a Schiff base and evaluated the antimicrobial activity.  
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Panneer Selvam T et al 
[31]
 synthesized a novel series of 2-substituted benzimidazole 
derivatives were synthesized and characterized. The compounds were screened for antibacterial 
and antifungal activity. The Minimum Inhibitory Concentrations was determined by vagar streak 
dilution method. 
 
N
N
H
N
S
O
R  
 
Ahamed A. Jafar et al 
[32]
 synthesized benzimidazole derivatives and screened them for 
antimicrobial activity. They synthesized 1H-tetrazol-1-yl) phenyl)-1H-benzo[d] imidazole by a 
series of conventional methods.  Antimicrobial activity against bacteria and fungi was studied. 
The results of preliminary biological tests showed that of these compounds possess good 
biological activities. 
 
N
N
H
NN
N
N
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 P.C Santhosh et al 
[33]
 have studied the versatility of the benzimidazole nucleus. Benzimidazole 
is a heterocyclic aromatic organic compound. This bicyclic compound consists of the fusion of 
benzene and imidazole. Benzimidazole is an extension of the well elaborated imidazole system 
has been used as carbon skeleton for N-heterocyclic carbines. They are found to have varied 
biological activities. 
 
 
Hamdan S. Al-Ebaisat 
[34]
 synthesized a set of six novel benzimidazoles compounds. The 
biological activity of these compounds as fungicides was tested against three commercially 
known fungicides (C. albicans, patient isolate C. glabrata and C. krusei).The biological activity 
of two compounds was found to be comparable to that of the commercially available fungicides  
N
NR1
R2
R3
 
 
 
Mohammad Shaharyar et al 
[35]
 synthesized 2-[2- (phenoxymethyl)-1H-benzimidazol-1-yl] 
acetohydrazide and few derivatives and screened the synthesized compounds for anticonvulsant 
activity. 
N
N
O
NH N
O
R  
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R. Walia et al 
[36]
 have summarized the chemistry of different derivatives of substituted 
benzimidazoles  along with their pharmacological activities. In the present research the new N-
(2-(1H-benzo[d]imidazol-2-yl) phenyl)-N-phenylbenzamide derivatives were synthesised. The 
reaction was carried out between o-phenylenediamine with substituted anthranilic acids. The 
resultant compounds were then refluxed with benzoyl chloride in the presence of pyridine to 
yield the product.The antimicrobial activity was evaluated against bacteria and fungi were 
studied. 
 
Y Radha et al 
[37]
 syntheised, characterized and evaluated some benzimidazole derivatives for 
antimycobacterial, cytotoxic and diuretica activity.Novel benzomidazole derivatives possessing 
two different structural moieties, pyridinyloxyphenyl benzimidazoles and indolyl benzimidazole 
were synthesized. 
NH
N
H
N
R1
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3) Reviews related to Schiff bases and their biological activities 
 
Vaibhav Sharma et al 
[38]
 reviewed on the chemistry and biological activities of Schiff bases. 
Schiff bases are the compounds which are mainly formed by the condensation of the aldehydes 
and amines. These compounds can be synthesized by various synthetic routes. Pharmacological 
actions of Schiff compounds which have been reported in previous studies are antimicrobial, 
antimalarial, antitubercular, anticancer, anthelmintic, analgesic, anti-inflammatory etc. 
 
 
 
 Khlood Fahed Hamak 
[39]
 synthesized Schiff base and evaluated it for antimicrobial 
activity.Schiff base were synthesis by the reaction of 2,6-bis (4-chlorophenyl) pipridone-4 with 
benzidine in ratio (2:1) and reaction of 3,5- dimethyl-2,6- diphenyl piperidone-4 with 1,2-
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Phenylendiamine and 2-aminobenzenethiol in ratio (1:1). All synthesized compound were 
characterized and evaluated for their in vitro antibacterial activities, against Gram positive 
(Staphylococcys aureus) and Gram negative (Escherichia.coli, Enterobacter, Salmonella, 
Klebsiella) bacteria. 
 
N
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Ahlam Marouf Al-Azzawi et al 
[40]
 synthesized a series of new Schiff bases linked to 
phthalimide through phenyl sulfonate moiety via multistep synthesis. Also a series of new Schiff 
bases linked to phthalimide through methylene group have been synthesized via reaction of 4- 
phenyl phenacyl bromide with phthalimide potassium salt producing compound which in turn 
introduced in reaction with different primary aromatic amines affording the new Schiff bases. 
N
O
O
S
O
O
O
NR  
 Kalpesh S. Parikh et al 
[41]
 designed and synthesized Schiff bases from acetopheneone.6-
Amino Indazole condensed with various aromatic acetophenone. Finally the product was 
characterized by conventional and instrumental methods.  
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                Amira S. Abd El-A et al 
[42]
 used efficient green chemistry for synthesizing a series of 
Schiff bases incorporating 4-1H-benzo[d] imidazole moiety, by microwave technique and 
heating conventional procedures which are used for their preparation. This work aims to make a 
comparison between conventional and microwave irradiation methods. The design of selected 
newly Schiff bases is defined by molecular modeling. The compounds were characterized and 
the evaluations of anticancer activities of compounds were done against human cancer cell lines. 
 
 
N
N
H
N
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Michael J. Hearn et al 
[43]
 synthesized and characterized Schiff bases of isoniazid and studied 
their antimycobacterial activity. Few structural modification of the isonicotinic acid hydrazide 
(INH) was performed which provides lipophilic adaptations of the drug in which the hydrazine 
moiety of the parent compound has been chemically blocked from the deactivating process of 
N2-acetylation by N-arylaminoacetyl transferases. 
 
4) Reviews related to biological evaluation of anti tubercular activity by MABA. 
 
Scott G.Franzblau et al 
[45]
 studied MIC determination by MABA. A colorimetric, microplate- 
based Alamar blur Assay (MABA) method was used to determine the MICs of Isoniazid, 
rifampin, streptomycin and ethambutol for 34 Peruvian Mycobacterium tuberculosis isolates and 
the H37Rv strain by using bacterial suspensions prepared directly from media. The MABA is a 
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simple, rapid, low-cost, appropriate technology which does not require expensive 
instrumentation and which makes use of a nontoxic, temperature-stable reagent. 
 
Sephra N.Rampresad 
[46]
 studied the various applications of Alamar blue as an indicator. 
Alamar Blue is an important redox indicator that is used to evaluate metabolic function and 
cellular health. The Alamar blue bioassay is being utilized to access cell viability and 
cytotoxicity in a range of biological and environmental system and in a number of cell types 
including bacteria, yeast, fungi,protozoa. 
 
Jose de Jesus Alba-Romero et al 
[47]
 applied the Alamar Blue assay to determine the 
susceptibility to anti-tuberculosis pharmaceuticals. The results showed that the MABA test is fast 
and easy to apply. It is a very reliable method of determining the drug susceptibility to 
pharmaceuticals. 
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MATERIALS AND METHODS 
 
A. DRUG DESIGN 
         A process of design and discovery of new chemical entities is done using an automated docking 
program GLIDE- Grid Based Ligand Docking with Energetics Maestro 9.4.047 Schrodinger Suite. 
 
           GLIDE is one of the docking programs which predicts the binding modes of ligand to a protein 
(target).It searches the ligands having maximum favourable interactions with a receptor usually a protein, 
Ligand is a single molecule where as the receptor may include proteins, metals and cofactors. 
 
           It runs on rigid and flexible docking modes. The latter generates conformations automatically for 
the input of each ligand and gives out the best fit pose of the molecule which has been docked to the 
receptor. 
 
           The docking procedure involves  
 Protein Preparation 
 Ligand Preparation 
 Receptor Grid Generation 
 Ligand Docking 
 
Protein Preparation 
 
            Protein preparation and refinement studies were performed on Glutamine Synthase 1.                                                            
The protein is downloaded from the Research Collaboratory for Structural Bioinformatics (RCSB) protein 
Data Bank with the following PDB id: 4ACF, resolution 2 Å using the protein preparation wizard of 
Maestro 9.4.047. A typical PDB structure consists of heavy atoms, metal ions, co factors, waters and can 
be multimeric. 
 
              The next step is to pre-process the protein structure by assignment of bond orders, tautomeric 
states and by the addition of polar hydrogen atoms. 
 
               Then only the ligand- receptor subunit is retained for the binding interaction of ligand and all the 
water molecules are deleted. 
 
                The final step is minimization of the protein structure by using force field OPLS _2005 to 
reorient side chain hydroxyl groups and alleviate potential steric clashes. 
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Ligand Preparation 
 
 The ligands were exported in a MDL file format into LigPrep tool of Maestro 9.4.047 version for ligand 
preparation. 
Ligand preparation involves optimization of geometric parameters prior to docking. The molecules 
designed for docking should have a 3D representation with realistic bond lengths and bond angles with 
filled valencies. Preparation process involves a series of steps which includes conversions, applying 
corrections and generating variations to the structures, there by rendering optimization. 
 
Receptor Grid Generation 
 
To perform the docking calculations more efficiently, the position, site and constraints of the receptor are 
mentioned to generate a receptor grid. In receptor grid generation the ligand is used to define the grid 
position and size. The receptor grid determines the size and position of the active site. This process is 
done using the Receptor Grid generation tool of Maestro 9.4.047 after the protein preparation process. 
 
Ligand Docking 
 
Docking was carried out by choosing the ligand grid base name file and the receptor grid base name file 
as output files which contains the 3D structures of the synthesized compounds and the receptor grid 
generated from prepared protein has the 3D structure of the enzyme respectively. 
The docking process calculates the binding energies of a particular conformation of the ligand to the 
receptor. Accessing the affinity of various ligands with particular receptor was carried out by Glide in the 
extra precision mode (XP). 
 
Docking Score  
 
The compounds are ranked based on G score which is obtained by the consideration of both rewards and 
penalties when the molecule interacts with the target. 
 
Rewards are represented by negative values. The basic parameters which are considered as rewards 
include lipophilic pair term, hydrophobic enclosure reward, hydrophobically packed hydrogen bond, 
hydrophobically packed correlated hydrogen bond, hydrogen bond pair term, chlorine and bromine, 
electrostatic rewards and sitemap ligand/receptor. Penalties value should be less for the best compounds. 
The basic parameters which are considered as penalties include hydrophobic ligand groups, rotatable 
bond and similarity. 
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B. IN-SILICO SCREENING OF DRUG LIKENESS 
For a drug to be pharmacologically active and exert the action it should posses pharmacokinetic 
properties like absorption, distribution, metabolism and excretion. In the field of drug research 
and development many drug failures occur due to unfavourable ADME properties. This has to be 
ruled out earlier in the process of drug discovery. Some computational methods (in silico tools) 
have been evolved to investigate the most suitable drug molecules before synthesis. 
Lipinski's rule of five also known as the Pfizer's rule of five is a rule to evaluate drug likeness. 
It is used to predict whether a molecule is likely to be orally bio-available or to evaluate drug 
likeness.
[48] 
Lipinski’s rule 
It is used to predict whether a molecule is likely to be orally bio-available or to evaluate drug 
likeness. The rule was formulated by Christopher A. Lipinski in 1997.The rule states that for 
drug likeness the molecule should have the following properties: 
 Molecular weight less than 500 Daltons 
 Calculated log P value less than 5 
 Less than 10 hydrogen bond acceptor groups( eg.-O-, -N-,etc) 
 Less than 5 hydrogen bond donor groups (eg. NH, OH, etc) 
 Less than 10 rotatable bonds 
The designed and docked molecules are screened in silico using Molinspiration 
Cheminformatics Software to evaluate drug likeness. This tool is quick and easy to use. It is a 
software available online  for calculation of important molecular properties (logP, polar surface 
area, number of hydrogen bond donors and acceptors and others), as well as prediction of 
bioactivity score for the most important drug targets (GPCR ligands, kinase inhibitors, ion 
channel modulators, nuclear receptors)
[49] 
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C. IN SILICO TOXCITY PREDICTION 
In silico toxicity prediction is done using OSIRIS Property Explorer. It is free software available 
for access in the Organic Chemistry Portal 
[15]
. Using this prediction tool, mutagenicity, 
tumorogenicity, skin irritancy, and reproductive effects can be calculated. The prediction 
properties relies on a precompiled set of structure fragment that gives rises to toxicity alerts in 
case they are encountered in the structure currently drawn. These fragment lists is created by 
rigorously shredding all compounds in the data base known to be active in a certain toxicity 
class. During the shredding any molecule is first cut at every rotatable bonds leading to a set of 
core fragments 
[53]
. Osiris software is used to calculate various drug relevant properties of 
chemical structures. The results are colour coded. The green colour represents that the compound 
is non-toxic. Yellow and red colour indicates moderate and severe toxicity of the chemicals 
respectively. 
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D. SYNTHETIC METHODOLOGY 
 
REACTANT PROFILE 
 
1. 4-NITRO O-PHENYLENEDIAMINE 
 
Structure:  
                        
N
+O
-
O
NH2
NH2
 
                 Synonym: 4-nitrobenzene-1,2-diamine 
                 Molecular Formula: C6H7N3O2 
                 Molecular Weight: 153.13 
                 Solubility: Soluble in DMSO, methanol 
                 Description:  Orange red powder 
                Melting Point: 201°C 
 
2. ANTHRANILIC ACID 
 
Structure:  
                      
NH2
O
OH
   
                 Synonym: 2-aminobenzoic acid 
                 Molecular Formula: C7H7NO2 
                 Molecular Weight: 137.13 
                 Solubility: Soluble in chloroform, ether, ethanol, hot water. 
                 Description:  Pale yellow or tan crystalline powder 
                 Melting Point: 148°C 
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3. Para- HYDROXY BENZALDEHYDE 
 
Structure:  
                      
O
OH    
                 Synonym: 4- hydroxyl benzaldehyde 
                 Molecular Formula: C7H6O2 
                 Molecular Weight: 122.12 
                 Solubility: Soluble in chloroform, acetonitrile, methanol and hot water. 
                 Description: Yellow to tan powder 
                 Melting Point: 114°C 
 
4. Para- DIMETHYL AMINO BENZALDEHYDE 
                 Structure:  
                     
O
N
CH3CH3
H
    
                 Synonym:  4- (dimethylamino) benzaldehyde 
                 Molecular Formula: C9H11NO 
                 Molecular Weight: 149.18 
                 Solubility: Soluble in chloroform,acetonitrile,hot ethanol.Slightly soluble in water. 
                 Description:  White crystalline powder 
                 Melting Point: 73°C 
 
 
 
 
Materials & Methods 
 
Dept of Pharmaceutical Chemistry, MMC Page 37 
 
5. 2-CHLORO 5-NITRO BENZALDEHYDE 
                 Structure:  
                     
Cl
N
+
O
-
O
O
H
    
                 Synonym: 2- chloro-5-nitro benzaldehyde 
                 Molecular Formula: C7H4ClNO3 
                 Molecular Weight: 185.56 
                 Solubility: Soluble in DMSO,chloroform, acetonitrile. 
                 Description:  Light yellow to beige yellow crystalline powder 
                Melting Point: 76°C 
 
6. FURFURALDEHYDE 
Structure:  
                        
O
O
H  
                 Synonym: Furan-2-Carbaldehyde 
                 Molecular Formula: C5H4O2 
                 Molecular Weight: 96.08 
                  Solubility: Soluble in methanol.Slightly soluble in water. 
                 Description: Colourless Oil  
                 Melting Point: -37°C 
                 Boiling Point: 162°C 
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7. PYRROLE 2 CARBOXALDEHYDE 
 
Structure:  
                     
N
H
O
H     
                 Synonym: 2-Formylpyrrole 
                 Molecular Formula: C5H5NO 
                 Molecular Weight: 95.10 
                 Solubility: Soluble in chloroform, DMSO, methanol. Insoluble in water. 
                Description:  Light yellow crystalline powder 
                Melting Point: 44°C 
 
 
INTERMEDIATE PROFILE 
 
 
Structure:  
                     
N
N
H NH2
N
+O
-
O     
                 Synonym: 2-(6-Nitro-1H-benzimidazol-2-yl)aniline 
                 Molecular Formula: C13H10N4O2 
                 Molecular Weight: 254.24 
                 Solubility: Soluble in DMSO, ethanol. Insoluble in water. 
                 Description:  Dark red needle shaped crystals 
                 Melting Point: 90°C 
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SYNTHESIS
 [51] 
 
 
STEP – 1 
 
 
 
N
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NH2
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+
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O
OH
N
N
H NH2
N
+O
-
O
4-nitrobenzene-1,2-diamine 2-aminobenzoic acid 2-(6-nitro-1H-benzimidazol-2-yl)aniline
Reflux 5-8 hrs
4 N HCl
 
 
 
 
STEP – 2 
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Ar2-(6-nitro-1H-benzimidazol-2-yl)aniline Aldehyde
Product
Ethanol
Stirring, r.t
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PROCEDURE 
 
 
STEP 1: PREPARATION OF 2-(6-NITRO-1H-BENZIMIDAZOL-2-YL) ANILINE
[36] 
  
 
        
   3.06 g (0.02 mole) of 4-nitro o- phenylene diamine and 2.64g (0.02 mole) anthranilic acid 
was taken in a round bottom flask. 50 ml of 4 N Hydrochloric acid was added to it. It was 
refluxed for 5-8 hours. To check the completeness of the reaction monitoring was done by 
TLC.After completion of the reaction, the mixture was poured into crushed ice. Sodium 
hydroxide was added drop wise till the solution was neutral to litmus. The precipitate obtained 
was filtered, washed with water, dried and recrystallised using ethanol. 
 
N
+O
-
O
NH2
NH2
+
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O
OH
N
N
H NH2
N
+O
-
O
4-nitrobenzene-1,2-diamine 2-aminobenzoic acid 2-(6-nitro-1H-benzimidazol-2-yl)aniline
Reflux 5-8 hrs
4 N HCl
 
 
  
STEP 2: PREPARATION OF SCHIFF BASE 
[50] 
 
 
0.01 mole of the product obtained in step 1 and 0.01 mole of the aldehyde were taken in a round 
bottom flask. 50 ml of ethanol was added to it and was stirred at room temperature for 10 to 15 
hours. The progress of the reaction was monitored by TLC. The product formed was filtered and 
dried. It was recrystallised using ethanol  
N
N
H NH2
N
+O
-
O
+ O
Ar
N
N
H
N
N
+
O
-
O
Ar2-(6-nitro-1H-benzimidazol-2-yl)aniline Aldehyde
Product
Ethanol
Stirring, r.t
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RECRYSTALLISATION 
 
            To the synthesized compound, warm ethanol was added and it was heated. The hot 
solution was filtered and the filtrate was collected in a china dish and allowed to cool. On 
cooling, crystals appeared.  
 
THIN LAYER CHROMATOGRAPHY 
 
              The reactants and products were dissolved in ethanol. It was spotted on the TLC plate. 
 
Stationary phase: Pre-coated Silica gel GF plates 
Mobile phase: Toluene: Ethyl Acetate: Formic Acid (5:4:1) 
Detection: UV chamber 
                
             A single principle spot for the product and the absence of secondary spots and spots for 
parent compounds confirmed the purity of the compound. 
 
CHARACTERISATION 
 
The synthesized compounds were identified by the following methods: 
 
1. MELTING POINT 
 
             The melting point of the synthesized compound was determined by one end open 
capillary tube method. The temperature at which the compound starts losing its crystallinity and 
changes from solid to liquid form was found and recorded. 
 
2. IR SPECTROSCOPY 
                  IR Spectroscopy helps to ascertain the presence and absence of the functional group. 
The synthesized compound was made into a pellet with potassium bromide by pressed pellet 
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technique using pellet press (Model No: M15) .The pellet was mounted on the pellet disc and 
percentage transmittance was recorded in ABB IR Spectrophotometer (Model No: MB 3000). 
 
3. NMR SPECTROSCOPY 
               Proton NMR Spectroscopy helps us to study the number of equivalent protons and their 
environment thereby we can ascertain the structure of the molecule. The NMR spectra was 
recorded on 300 MHz BRUKER Advance III NMR Spectrometer. DMSO was used as solvent. 
 
4. MASS SPECTROSCOPY 
                 Mass Spectroscopy enables us to establish the molecular mass of the compound. The 
mass spectra of the synthesized compounds were recorded in Q-Tof-Mass Spectrometer (Q-Tof 
micro hybrid quadrupole time of flight mass spectrometer) with electrospray ionization (ESI) and 
in JEOL GCMATE II GC-MS. 
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E. IN VITRO ANTITUBERCULAR ACTIVITY 
 
Anti-TB activity using Alamar Blue Dye 
[52] 
 
PROCEDURE 
 
1) The anti mycobacterial activity of compounds were assessed against M. tuberculosis 
using microplate Alamar Blue assay (MABA). 
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method. 
3) Briefly, 200µl of sterile deionzed water was added to all outer perimeter wells of sterile 
96 wells plate to minimize evaporation of medium in the test wells during incubation. 
4) The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial dilution of 
compounds were made directly on plate. 
5) The final drug concentrations tested were 100 to 0.2 µg/ml. 
6) Plates were covered and sealed with parafilm and incubated at 37ºC for five days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs.  
8) A blue color in the well was interpreted as no bacterial growth, and pink color was scored 
as growth.  
9) The MIC was defined as lowest drug concentration which prevented the color change 
from blue to pink. 
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RESULTS AND DISCUSSION 
 
A. DRUG DESIGN 
The designed molecules were docked against the selected target- Glutamine Synthase 1.Extra 
precision mode molecular docking was executed for perfect docking of the ligand into the cavity 
of the protein having active site. During the docking procedure different poses of the ligand were 
generated and the ligands were docked in different poses. The best docked pose was selected 
based on the G.Score generated and the interactions between the protein and the ligand. There 
were hydrogen bond interactions between all the five molecules and the active site. Hydrophobic 
interactions are also seen. 
 
DOCKING SCORE OF THE COMPOUNDS 
 
N
H
N
N
N
+
O
-
O
OH
                         
N
H
N
N
N
+O
-
O
N
CH3
CH3
 
Compound Id: SSS-HBZ                                                     Compound Id: SSS-DMAB 
            G.Score: -6.72 kcal/mol                                                         G.Score: -4.97kcal/mol 
 
N
H
N
N
N
+O
-
O
Cl
N
+
O
-
O
                            
N
H
N
N
N
+
O
-
O
O
 
Compound Id: SSS-CNBZ                                                    Compound Id: SSS-FUR 
   G.Score: -6.65 kcal/mol                                                         G.Score: -6.64kcal/mol 
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N
H
N
N
N
+
O
-
O
N
H
 
Compound Id: SSS-PC 
G.Score: -5.49kcal/mol 
 
 
DOCKING SCORE OF THE STANDARD DRUGS 
 
 
NH2
NH
O
N
                                               O
NH2
NN
 
                           Isoniazide            Pyrazinimide 
                    G.Score: -4.4 kcal/mol     G.Score: -4.1 kcal/mol 
 
 
 
 
OH
O
N N
NH
F
O
 
                                                                  Ciprofloxacin                   
  G.Score: -6.5 kcal/mol 
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COMPOUNDS DOCKED AGAINST THE PROTEIN 4ACF 
 
 
            
Fig 7: SSS- HBZ with 4 ACF                                         Fig 8: SSS-DMAB with 4 ACF 
 
 
            
Fig 9: SSS- CNBZ with 4 ACF                                        Fig 10: SSS-FUR with 4 ACF 
 
 
Fig 11: SSS-PC with 4 ACF 
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INTERACTIONS BETWEEN THE COMPOUNDS AND THE PROTEIN 
 
         Key:                                     
 
 
 
 
   
Fig 12: Interactions of SSS- HBZ with 4ACF     Fig 13: Interactions of SSS-DMAB with 4ACF 
 
 
    
Fig 14: Interactions of SSS- CNBZ with 4ACF       Fig 15: Interactions of SSS-FUR with 4ACF 
 
Hydrophobic Interaction 
- - - - - - - - - - - - - Hydrogen bond Interaction 
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Fig 16: Interactions of SSS- CNBZ with 4ACF   
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Table 1: Rewards 
 
 
Ligand G.Score 
Dock 
Score 
Lipophilic 
EvdW PhobEn 
PhobEn 
HB 
PhobEn 
PairHB HBond Electro Sitemap iCat ClBr LowMW 
SSS-HBZ -6.72 -6.49 -4.1 -0.47 -1.5 0 -1.26 -0.21 -0.15 0 0 -0.31 
SSS-DMAB -4.97 -4.74 -3.34 0 -1.5 0 -0.66 -0.29 -0.12 0 0 -0.22 
SSS-CNBZ -6.65 -6.42 -4.7 -0.68 -1.5 0 -0.66 -0.11 -0.21 0 0 -0.09 
SSS-FUR -6.94 -6.71 -4.17 -0.53 -1.5 0 -0.66 -0.15 -0.24 0 0 -0.39 
SSS-PC -5.49 -5.26 -3.91 0 -1.5 0 -0.66 -0.19 -0.19 0 0 -0.4 
 
             
   Table 2: Penalties 
 
 
Ligand Penalties HBPenal ExposPenal RotPenal EpikStatePenalty Similarity Activity 
SSS-HBZ 0 0 1.09 0.19 0.23 1 -6.72 
SSS-DMAB 0 0 0.98 0.17 0.23 1 -4.97 
SSS-CNBZ 0 0 1.16 0.14 0.23 1 -6.65 
SSS-FUR 0 0 0.49 0.22 0.23 1 -6.94 
SSS-PC 0 0 1.13 0.22 0.23 1 -5.49 
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B. IN-SILICO SCREENING OF DRUG LIKENESS 
 
  All the 5 compounds were screened for drug likeness by using Molinspiration Cheminformatics 
Software. On screening it was found that the ADME parameters were within the range. 
 
 
 
Molinspiration property engine 
v2013.09 
 
miLogP         4.486 
TPSA           107.099 
natoms         27.0 
MW             358.357 
nON            7 
nOHNH          2 
nviolations    0 
nrotb          4 
volume         306.294 
 
 
 
 
 
Fig 17: Screenshot of SSS-HBZ screening of drug likeness in Molinspiration 
 
 
 
 
Molinspiration property engine 
v2013.09 
 
miLogP         5.067 
TPSA           90.109 
natoms         29.0 
MW             385.427 
nON            7 
nOHNH          1 
nviolations    1 
nrotb          5 
volume         344.182 
 
 
 
 
 
Fig 18: Screenshot of SSS-DMAB screening of drug likeness in Molinspiration 
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Molinspiration property engine 
v2013.09 
 
miLogP         5.53 
TPSA           132.695 
natoms         30.0 
MW             421.8 
nON            9 
nOHNH          1 
nviolations    1 
nrotb          5 
volume         335.146 
 
 
 
 
 
Fig 19: Screenshot of SSS-CNBZ screening of drug likeness in Molinspiration 
 
 
 
 
 
Molinspiration property engine 
v2013.09 
 
miLogP         4.222 
TPSA           100.011 
natoms         25.0 
MW             332.319 
nON            7 
nOHNH          1 
nviolations    0 
nrotb          4 
volume         279.844 
 
 
 
 
 
Fig 20: Screenshot of SSS-FUR screening of drug likeness in Molinspiration 
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Molinspiration property engine v2013.09 
 
miLogP         4.119 
TPSA           102.662 
natoms         25.0 
MW             331.335 
nON            7 
nOHNH          2 
nviolations    0 
nrotb          4 
volume         283.262 
 
 
 
 
 
Fig 21: Screenshot of SSS-PC screening of drug likeness in Molinspiration 
 
 
 
Compound miLog 
P 
TPSA natoms MW nON nOHNH nviolations nrotb Volume 
SSS-HBZ 4.486 107.099 27.0 358.357 7 2 0 4 306.294 
SSS-
DMAB 
5.067 90.109 29.0 385.427 7 1 1 5 344.182 
SSS-CNBZ 5.53 132.695 30.0 421.8 9 1 1 5 335.146 
SSS-FUR 4.222 100.011 25.0 332.319 7 1 0 4 279.844 
SSS-PC 4.119 102.662 25.0 331.335 7 2 0 4 283.262 
 
 
Table 3: Values for In-silico drug likeness assessment 
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C. IN SILICO TOXCITY PREDICTION 
 
In silico toxicity prediction was done for the filtered 5 compounds using OSIRIS Property 
Explorer. This software is available for access in the Organic Chemistry Portal 
[15]
. Using this 
prediction tool, mutagenicity, tumorogenicity, skin irritancy, and reproductive effects were 
calculated. The results were colour coded. The green colour represents that the compound is non-
toxic. Yellow and red colour indicates moderate and severe toxicity of the chemicals 
respectively. 
 
            
 
Fig 35: Toxicity prediction for SSS-HBZ                    Fig 36: Toxicity prediction for SSS-DMAB  
 
           
 
Fig 37: Toxicity prediction for SSS-CNBZ                 Fig 38: Toxicity prediction for SSS-FUR 
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Fig 37: Toxicity prediction for SSS-PC  
 
            
 
Compound 
Code 
Mutagenicity Tumorogenicity Skin Irritancy Reproductive 
Effect 
SSS-HBZ Green Green Green Green 
SSS-DMAB Green Red Green Green 
SSS-CNBZ Yellow Green Yellow Green 
SSS-FUR Green Green Green Green 
SSS-PC Yellow Green Green Green 
     
  
Table 6: Toxicity Predicition using OSIRIS 
 
Compounds SSS-HBZ and SSS-FUR were predicted to be non-toxic. SSS-CNBZ and SSS-PC 
were predicted to be moderately mutagenic and SSS-DMAB was predicted to be severely 
tumorogenic. 
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D. SYNTHESIS AND CHARACTERIZATION 
 
 
      The synthetic scheme was drawn for the filtered 5 compounds from docking and the 
procedure for synthesis was collected from literature. The necessary chemicals of laboratory 
grade were procured and synthesis was carried out after the optimization of the reaction 
conditions. Products were obtained with a yield of about 77% and then recrystallised. The 
physical properties such as appearance, solubility, melting point were recorded uncorrected and 
tabularized below. 
 
 
Compound Molecula
r Weight 
Molecular 
Structure 
Solubility Melting 
Point 
Appearance 
SSS-HBZ 360.36 
N
H
N
N
N
+
O
-
O
OH
 
Dimethyl 
Sulphoxide, 
Acetonitrile 
217ºC Brown 
coloured 
powder 
SSS-
DMAB 
385.41 
N
H
N
N
N
+O
-
O
N
CH3
CH3
 
Dimethyl 
Sulphoxide, 
Acetonitrile 
165ºC Dark red 
coloured 
powder 
SSS-CNBZ 421.79 
N
H
N
N
N
+O
-
O
Cl
N
+
O
-
O
 
Dimethyl 
Sulphoxide, 
Acetonitrile 
150 ºC Dark brown 
coloured 
powder 
SSS-FUR 332.31 
N
H
N
N
N
+
O
-
O
O
 
Dimethyl 
Sulphoxide, 
Acetonitrile 
128 ºC Brown 
coloured 
crystalline 
powder 
SSS-PC 331.32 
N
H
N
N
N
+
O
-
O
N
H
 
Dimethyl 
Sulphoxide, 
Acetonitrile 
200 ºC Dark Reddish 
crystals 
 
 
Table 4: Physical Properties of the synthesized compounds 
 
 
                   Further the products were characterized and the purity was justified by taking the 
melting point, running TLC, IR Spectroscopy, NMR Spectroscopy and Mass Spectroscopy. The 
results are interpreted along with the spectra below. 
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COMPOUND SSS-HBZ 
 
a. IR SPECTROSCOPY 
 
 
 
 
Fig 22: IR Spectra of SSS-HBZ 
 
 
Compound IR Absorption Region  Interpretation 
SSS-HBZ 1442.65 cm
-1
 
2923.87 cm
-1
 
3286.46 cm
-1
  
3425.33 cm
-1
 
1334.61 cm
-1
 
1512.08 cm
-1 
C=C Aromatic Stretching 
C-H Aliphatic Stretching 
N-H 2º Amine Stretching 
O-H Hydroxyl Stretching 
N=O ( Ar-NO2 ) Stretching 
C=N Stetching in Heterocyclic Rings 
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b. NMR SPECTROSCOPY 
 
 
 
Fig 23:  NMR Spectra for SSS- HBZ 
 
Compound 
1
H NMR Data 
SSS-HBZ δ 2.45- 2.53 ( s, 1H, Aliphatic H) 
δ 5.52- 5.61 ( s, 1H, Hydroxyl H) 
δ 6.53- 6.78 ( d, 1H, Aromatic H) 
δ 6.78- 6.89 ( d, 1H, Aromatic H) 
δ 6.89- 7.02 ( t, 2H, Aromatic H) 
δ 7.58- 7.78 ( d, 2H, Aromatic H) 
δ 7.78- 7.89 ( d, 1H, Aromatic H) 
δ 8.01- 8.17 ( m, 2H, Aromatic H) 
δ 8.38- 8.48 ( s, 1H, Aromatic H) 
δ 9.45- 9.55 ( s, 1H, Aromatic H) 
δ 10.12- 10.28 ( m, 1H, Aromatic H) 
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c. MASS SPECTROSCOPY 
 
 
 
Fig 24: Mass Spectra for SSS- HBZ 
 
Compound Mol. formula / Mol. Wt  
calculated 
m/e value 
Relative abundance 
SSS-HBZ C20H14N4O3 / 358.35 
 
 
359 (M
+
)  
256 (B) 
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COMPOUND SSS-DMAB 
a. IR SPECTROSCOPY 
 
 
 
Fig 25: IR Spectra of SSS-DMAB 
 
Compound IR Absorption region  Interpretation 
SSS-DMAB 1434.93 cm
-1
 
2916.16 cm
-1
 
3348.18 cm
-1
  
1288.35 cm
-1
 
1519.80 cm
-1 
1026.05 cm
-1
 
C=C Aromatic Stretching 
C-H Aliphatic Stretching 
N-H 2º Amine Stretching 
N=O ( Ar-NO2 ) Stretching 
C=N Stetching in Heterocyclic Rings 
C-N Stretching 
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b. NMR  SPECTROSCOPY 
 
Fig 26: NMR Spectra for SSS- DMAB 
 
Compound 
1
H NMR Data 
SSS-DMAB δ 2.45- 2.97 ( d, 3H, Aliphatic H) 
δ 2.97- 3.18 ( d, 3H, Aliphatic H) 
δ 5.08- 5.19 ( s, 1H, Aliphatic H) 
δ 6.02- 6.11 ( s, 1H, Aromatic H) 
δ 6.18- 6.75 ( d, 2H, Aromatic H) 
δ 6.75-7.01 ( m, 2H, Aromatic H) 
δ 7.34- 7.49 ( d, 1H, Aromatic H) 
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c. MASS SPECTROSCOPY 
 
 
 
Fig 27: Mass Spectra for SSS- DMAB 
 
Compound Mol. formula / Mol. Wt  
calculated 
m/e value 
Relative abundance 
SSS-DMAB C22H19N5O2 / 385.41856 
 
386 (M
+
)  
283 (B) 
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COMPOUND SSS-CNBZ 
 
a. IR SPECTROSCOPY 
 
 
 
Fig 28: IR Spectra of SSS-CNBZ 
 
Compound IR Absorption region  Interpretation 
SSS-CNBZ 1481.22 cm
-1
 
2923.87 cm
-1
 
3093.59 cm
-1
  
3355.89 cm
-1
 
1350.07 cm
-1
 
1519.80 cm
-1 
740.61 cm
-1
 
C=C Aromatic Stretching 
C-H Aliphatic Stretching 
C-H Aromatic Stretching 
N-H 2º Amine Stretching 
N=O ( Ar-NO2 ) Stretching 
C=N Stetching in Heterocyclic Rings 
C-Cl Stretching 
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b. NMR SPECTROSCOPY 
 
 
 
Fig 29: NMR Spectra for SSS- CNBZ 
 
Compound 
1
H NMR Data 
SSS-CNBZ δ 1.11-1.40 ( s, 1H, Aliphatic H) 
δ 6.31-6.51 ( d, 1H, Aromatic H) 
δ 6.52-6.95 ( d, 1H, Aromatic H) 
δ 6.95-7.28 ( d, 2H, Aromatic H) 
δ 7.28-7.69 ( d, 1H, Aromatic H) 
δ 7.69-7.97 ( m, 2H, Aromatic H) 
δ 8.10-8.31 ( m, 1H, Aromatic H) 
δ 8.31-8.42 ( s, 1H, Aromatic H) 
δ 8.91-9.22 ( s, 1H, Aromatic H) 
 
Results & Discussion 
 
Dept of Pharmaceutical Chemistry, MMC Page 64 
 
c. MASS SPECTROSCOPY 
 
 
 
Fig 30: Mass Spectra for SSS- CNBZ 
 
Compound Mol. formula / Mol. Wt  
calculated 
m/e value 
Relative abundance 
SSS-CNBZ C20H12ClN5O4/ 421.79338 
 
422 (M
+
)  
301 (B) 
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COMPOUND SSS-FUR 
 
a. IR SPECTROSCOPY 
 
 
 
Fig 31: IR Spectra of SSS-FUR 
 
Compound IR Absorption region  Interpretation 
SSS-FUR 1481.22 cm
-1
 
2916.16 cm
-1
 
3186.17 cm
-1
  
3309.61 cm
-1
 
1303.78 cm
-1
 
1581.51 cm
-1 
887.19 cm
-1
 
C=C Aromatic Stretching 
C-H Aliphatic Stretching 
C-H Aromatic Stretching 
N-H 2º Amine Stretching 
N=O ( Ar-NO2 ) Stretching 
C=N Stetching in Heterocyclic Rings 
C-O Stretching in Heterocyclic Rings 
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b. NMR SPECTROSCOPY 
 
 
 
Fig 32: NMR Spectra for SSS- FUR 
 
Compound 
1
H NMR Data 
SSS-FUR δ 2.42- 2.59 ( s, 1H, Aliphatic H) 
δ 6.56- 6.68( s, 2H, Aromatic H) 
δ 6.71- 6.82 ( m, 3H, Aromatic H) 
δ 7.23- 7.29 ( d, 1H, Aromatic H) 
δ 7.86- 8.03 ( m, 4H, Aromatic H) 
δ 8.16- 8.66 ( s, 1H, Aromatic H) 
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c. MASS SPECTROSCOPY 
 
 
 
Fig 33: Mass Spectra for SSS- FUR 
 
Compound Mol. formula / Mol. Wt  
calculated 
m/e value 
Relative abundance 
SSS-FUR C18H12N4O3 /332.31288 
 
331.56 (M
+
)  
252.09 (B) 
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COMPOUND SSS-PC 
 
a. IR SPECTROSCOPY 
 
 
 
Fig 34: IR Spectra of SSS-PC 
 
Compound IR Absorption region  Interpretation 
SSS-PC 1465.79 cm
-1
 
2923.87 cm
-1
 
3101.31 cm
-1
  
3340.46 cm
-1
 
1303.78 cm
-1
 
1519.80 cm
-1 
C=C Aromatic Stretching 
C-H Aliphatic Stretching 
C-H Aromatic Stretching 
N-H 2º Amine Stretching 
N=O ( Ar-NO2 ) Stretching 
C=N Stetching in Heterocyclic Rings 
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b. NMR SPECTROSCOPY 
 
 
 
Fig 35: NMR Spectra for SSS- PC 
 
Compound 
1
H NMR Data 
SSS-PC δ 2.39- 2.55 ( s, 1H, Aliphatic H) 
δ 6.05- 6.23 ( s, 4H, Aromatic H) 
δ 6.42- 6.64 ( d, 2H, Aromatic H) 
δ 7.30- 7.55 ( m, 4H, Aromatic H) 
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c. MASS SPECTROSCOPY 
 
 
 
Fig 33: Mass Spectra for SSS- PC 
 
Compound Mol. formula / Mol. Wt  
calculated 
m/e value 
Relative abundance 
SSS-PC C18H13N5O2 / 331.32812 331.12 (M
+
)  
152.86 (B) 
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E. IN VITRO ANTITUBERCULAR ACTIVITY 
 
 
The anti-tubercular activity of the synthesized compounds was determined by Microplate Alamar 
Blue Assay (MABA) according to the procedure given in the materials and methods. 
 
All the synthesized compounds showed antimycobacterial activity against the M.tuberculosis 
strain tested. The organism was susceptible to all the synthesized compounds and the minimum 
inhibitory concentration for the compounds varied between 100-50 µg/ml. Pyrazinamide (3.125 
µg/ml), Streptomycin (6.25 µg/ml) and Ciprofloxacin (3.125 µg/ml) were used as standard. The 
data pertaining to this is presented as table. 
 
Among the synthesized compounds all the compounds showed activity at 50 µg/ml except SSS-
HBZ which showed activity at 100 µg/ ml. The picture below indicates the activity of the 
compound at the various dilutions. 
 
 
Fig 34: Anti tubercular activity by MABA for the synthesized compounds 
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Sl.No Samples 100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1. SSS-HBZ S R R  R R R R R 
2. SSS-DMAB S S R R R R R R 
3. SSS-CNBZ S S R R  R R R R 
4. SSS-FUR S S R R R R R R 
5. SSS-PC S S R R R R R R 
 
Table 5: Anti tubercular activity at various concentrations by MABA 
 
NOTE: 
S-Sensitive 
R-Resistant 
Strain Used: M.tuberculosis (H37 RV Strain) 
 
Standard values: 
Pyrazinimide- 3.125 µg/ml 
Streptomycin-6.25 µg/ml 
Ciprofloxacin- 3.125 µg/ml 
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SUMMARY 
 
Glutamine Synthase I is a vital enzyme present in the cell wall of Mycobacterium tuberculosis 
H37Rv.It belongs to the Ligase family. 
 
This enzyme was chosen as the target for the drug design study after thorough literature review. 
A database of 100 molecules with potential to inhibit the target (PDB id: 4ACF) was chosen by 
altering the lead molecule, 6-nitro benzimidazole. 
 
The designed molecules were docked against the target chosen using Schrodinger‟s GLIDE® 
(Grid Based Ligand Docking with Energetics. 
 
From among the docked molecules, 5 molecules with good Glide score were chosen for 
laboratory synthesis. The drug likeness and toxicity prediction was carried out for the filtered 5 
compounds in silico. 
 
Then further the compounds were synthesized. The reaction conditions were optimized. 
 
The compounds were labeled as SSS-HBZ, SSS-DMAB, SSS-CNBZ, SSS- FUR and SSS-PC 
and synthesized and recrystallised. 
 
The purity of the synthesized compounds were evaluated by melting point and TLC and were 
characterized by Infrared Spectroscopy, Nuclear Magnetic Resonance Spectroscopy and Mass 
Spectroscopy. 
 
The purified compounds were screened for antitubercular activity by invitro Micro Plate Alamar 
Blue Assay. 
 
The Minimum Inhibitory Concentration (MIC) of all the synthesized compounds were at 50 µg 
/ml except SSS-HBZ which was at 100 µg/ml against the MIC of known TB drugs 
Pyrazinamide: 3.125 mcg/ml, Ciprofloxacin: 3.125 mcg/ml and Streptomycin 6.25 mcg/ml. 
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CONCLUSION 
 
It is concluded that the synthesized compounds might effectively inhibit the chosen target, 
Glutamine Synthase 1 which is essential for the growth of the Mycobacterium tuberculosis. 
Further structural modifications of the synthesized compounds will aid in the development of 
potential molecules against the pathogen.  
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